Pricing

Alterity Therapeutics Ltd (ATHE)

followers ·
Sector:
MATERIALS
Industry:
CHEMICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David A. Stamler
Employees:
10
LEVEL 3, 460 BOURKE STREET, MELBOURNE, C3, VIC 3000
61 3 9349 4906
    Formally known as:
  • Prana Biotechnology Ltd Foreign Ordinary
Stock Split History
DateRatio
2016-03-24 1:6
2023-01-09 1:10
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's Disease.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available